Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 9:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 573 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Novo Nordisk A/S Clear all
Terminated Phase 3 Interventional Results available

Binge Eating Liraglutide Intervention

NCT03279731
View directory record Official record
Conditions
Binge-Eating Disorder
Interventions
Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml, Placebo
Drug
Lead sponsor
Kelly Allison
Other
Eligibility
21 Years to 70 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 24, 2020 · Synced Oct 13, 2026, 9:10 PM EDT
Completed Phase 1 Interventional

Effect of Renal Impairment on the Pharmacokinetics of NN9535

NCT00833716
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2, Renal Impairment
Interventions
semaglutide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Oct 13, 2026, 9:10 PM EDT
Terminated Phase 2 Interventional

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

NCT01636817
View directory record Official record
Conditions
Inflammation, Rheumatoid Arthritis
Interventions
NNC0109-0012, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
92
States / cities
Huntsville, Alabama • Tuscaloosa, Alabama • Mesa, Arizona + 81 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2018 · Synced Oct 13, 2026, 9:10 PM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Participants With Nonalcoholic Steatohepatitis (NASH)

NCT03987074
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
Semaglutide, Firsocostat, Cilofexor
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
18
States / cities
Chandler, Arizona • Coronado, California • La Jolla, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2021 · Synced Oct 13, 2026, 9:10 PM EDT
Completed Phase 1 Interventional

Single Dose Pharmacokinetics of Repaglinide, Metformin and Combination Tablet in Fed Healthy Volunteers

NCT01490658
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
repaglinide, metformin, repaglinide and metformin combination tablet
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 45 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 10, 2017 · Synced Oct 13, 2026, 9:10 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Impact of Continuing Medical Education (CME) Insulin Program

NCT00824603
View directory record Official record
Conditions
Diabetes
Interventions
Not listed
Lead sponsor
HealthPartners Institute
Other
Eligibility
25 Years and older
Enrollment
294 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 2, 2015 · Synced Oct 13, 2026, 9:10 PM EDT
Completed Phase 3 Interventional Results available

Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin

NCT02963922
View directory record Official record
Conditions
Metabolism and Nutrition Disorder, Obesity
Interventions
Liraglutide 3.0 mg, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
19
States / cities
Birmingham, Alabama • Concord, California • Fresno, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2020 · Synced Oct 13, 2026, 9:10 PM EDT
Completed Phase 3 Interventional Results available

Comparison of Two Insulin Degludec Formulations in Subjects With Type 2 Diabetes Mellitus

NCT01364428
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
373 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
45
States / cities
Huntsville, Alabama • Goodyear, Arizona • Mesa, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2017 · Synced Oct 13, 2026, 9:10 PM EDT
Completed Phase 2 Interventional Results available

A Research Study to Look Into How Well Semaglutide Medicine Works at Different Doses in People With Type 2 Diabetes and Overweight

NCT05486065
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Semaglutide, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 64 Years
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
101
States / cities
Birmingham, Alabama • Banning, California • Chula Vista, California + 83 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2025 · Synced Oct 13, 2026, 9:10 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Treatment to Regress to Normoglycemia in Women with a Recent History of GDM

NCT04873050
View directory record Official record
Conditions
Pre Diabetes, Postpartum Disorder
Interventions
Semaglutide Pen Injector [Ozempic], Placebo semaglutide pen injector
Drug
Lead sponsor
Woman's
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Oct 13, 2026, 9:10 PM EDT
Recruiting Phase 1 Interventional

Safety, Tolerability, and Pharmacokinetics of DCR-PDL1 in Adults With Solid Tumors

NCT06504368
View directory record Official record
Conditions
Solid Tumors, Adult
Interventions
DCR-PDL1
Drug
Lead sponsor
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Irving, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Oct 13, 2026, 9:10 PM EDT
Completed Phase 3 Interventional Results available

IDegLira HIGH Trial

NCT03737240
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
IDegLira, Insulin Degludec (U-100), Insulin Aspart
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 8, 2023 · Synced Oct 13, 2026, 9:10 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Research Study Looking at How Well Semaglutide Works in People Suffering From Obesity and Knee Osteoarthritis

NCT05064735
View directory record Official record
Conditions
Obesity
Interventions
semaglutide 2.4 mg, semaglutide 2.4 mg (placebo)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
Not listed
Enrollment
407 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
61
States / cities
Montgomery, Alabama • Phoenix, Arizona • Anaheim, California + 52 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Oct 13, 2026, 9:10 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of FT 4101 in Overweight/Obese Participants With Non-alcoholic Steatohepatitis

NCT04004325
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis (NASH), Overweight or Obesity
Interventions
FT-4101, FT-4101 placebo, Deuterated Water
Drug · Other
Lead sponsor
Forma Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Chula Vista, California • Montclair, California
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 13, 2026, 9:10 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus.

NCT02849080
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
semaglutide, sitagliptin
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
504 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
37
States / cities
Glendale, Arizona • Phoenix, Arizona • Lancaster, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2022 · Synced Oct 13, 2026, 9:10 PM EDT
Completed Phase 4 Interventional

Efficacy of Biphasic Insulin Aspart 30 in Type 2 Diabetics Failing on OADs

NCT00791895
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
biphasic insulin aspart 30
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
15
States / cities
Phoenix, Arizona • La Jolla, California • DeLand, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2017 · Synced Oct 13, 2026, 9:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Research Study to Investigate How a Study Medicine (NNC9204- 1177) Affects Blood Levels of Other Medicines in Healthy People

NCT04059367
View directory record Official record
Conditions
Healthy Volunteers, Overweight, Obesity
Interventions
NNC9204-1177, Cocktail of 5 already approved drugs
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 60 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 22, 2020 · Synced Oct 13, 2026, 9:10 PM EDT
Completed Phase 4 Interventional

Comparing Semaglutide Versus Placebo on Intestinal Barrier Function in Type 2 Diabetes Mellitus (SIB)

NCT04979130
View directory record Official record
Conditions
Type 2 Diabetes, Chronic Inflammation, Intestinal Permeability
Interventions
Semaglutide, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 89 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Oct 13, 2026, 9:10 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes

NCT03136484
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
Semaglutide, Canagliflozin, Placebo (canagliflozin), Placebo (semaglutide)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
788 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
57
States / cities
Anaheim, California • La Mesa, California • Los Angeles, California + 43 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2020 · Synced Oct 13, 2026, 9:10 PM EDT
Completed Phase 2 Interventional Results available

Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)

NCT04971785
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
Semaglutide (SEMA), Cilofexor (CILO)/Firsocostat (FIR), PTM SEMA, PTM CILO/FIR
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 80 Years
Enrollment
457 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
175
States / cities
Birmingham, Alabama • Dothan, Alabama • Madison, Alabama + 137 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2025 · Synced Oct 13, 2026, 9:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Research Study to Compare How Much Semaglutide is Found in the Blood With Different Tablets of Oral Semaglutide in Healthy Participants

NCT05784402
View directory record Official record
Conditions
Healthy Participants
Interventions
Semaglutide J, Semaglutide C
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 64 Years
Enrollment
264 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
2
States / cities
Cypress, California • Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Oct 13, 2026, 9:10 PM EDT
Completed Phase 1 Interventional

Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects

NCT02490787
View directory record Official record
Conditions
Congenital Bleeding Disorder, Haemophilia A
Interventions
Concizumab, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 64 Years · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
8
States / cities
Torrance, California • Indianapolis, Indiana • Iowa City, Iowa + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2017 · Synced Oct 13, 2026, 9:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Research Trial Looking at the Comparability of 2 Different Concentrations of Semaglutide for the 0.5 Milligram (mg) Dose

NCT05689099
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Healthy Participants
Interventions
Semaglutide B, 1.34 mg/mL, Semaglutide B, 0.68 mg/mL
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 13, 2026, 9:10 PM EDT
Recruiting Phase 3 Interventional

AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications

NCT07797335
View directory record Official record
Conditions
Type 2 Diabetes, Cardiovascular Risk
Interventions
Zenagamtide, Insulin glargine U-100
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
45 Years and older
Enrollment
1,778 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
109
States / cities
Birmingham, Alabama • Fairhope, Alabama • Montgomery, Alabama + 91 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 13, 2026, 9:10 PM EDT